Phase 2 N=13 Suvorexant for Opioid/Stimulant Co-use
Opioid Use Disorder · Stimulant Use Disorder
Primary: Opioid Use: Proportion of Positive Urine Drug Screens (UDS) — 0.83; 0.67 Proportion of urine drug screens
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=20 Oxytocin, Stress, Craving, Opioid Use Disorder
Opioid Use Disorder
Primary: Opioid Craving — 21.6; 22.4; 23.3; 23.4 score on a scale
Phase 2 N=40 Stimulant Oxytocin Study
Stimulant Use & Co-occuring Opioid Use Disorders
Primary: Number of Participants With Stimulant Positive Drug Screen — 9; 12; 9; 10 Participants
N/A N=119 Stress Response in Opioid Use Disorder
Opioid-use Disorder
Primary: Change in Negative Affect — 1.67; 1.25; 3.60 scores on a scale
N/A N=29 Initiating Substance Use Disorder Treatment for Hospitalized Opioid Use Disorder Patients.
Opioid-use Disorder
Primary: Treatment Retention — 5; 5 Participants — p==0.87
N/A N=78 Stress, Distress Intolerance, and Drug Dependence
Substance Dependence
Primary: Percentage of Positive Toxicology Swabs for Illicit Substances — 81.3; 79.1; 86.2; 82.3 percentage of positive toxicology screen
N/A N=112 Co-Use of Opioid Medications and Alcohol Prevention Study
Alcohol Drinking · Opioid Use
Primary: Alcohol Use Reductions — 11; 12; 1; 1 Participants
Phase 3 N=471 Stimulant Abuser Groups to Engage in 12-Step
Drug Abuse
Primary: Days of Stimulant Use — 2.35; 2.13 days of stimulant use — p=<0.05
N/A N=81 Using Combined EEG and Non-invasive Brain Stimulation to Examine and Improve Reward Functioning in Opioid Use Disorder
Opioid-use Disorder
Primary: Reward Positivity — -5.2; -2.3; -4.4; -4.6 μV (microvolts)
Phase 1 N=73 Oxytocin Suppresses Substance Use Disorders Associated With Chronic Stress
Alcohol Use Disorders
Primary: Alcohol Craving — 2.89; 3.08 scores on a scale
N/A N=62 Stigma and a Shared Decision Aid
Opioid Use Disorder
Primary: Patient Internalized Stigma Towards Medicaid for Opioid Use Disorder (MOUDs) Over the Course of the Project — 15; 11; 14; 8 score on a scale — p=0.32
Phase 1 N=27 Drug Interaction and Subjective Effects of Compounds for Opioid Use Disorder
Opioid Abuse · Opioid Dependence · Opioid-Related Disorders
Primary: Change in Subjective Response to Oxycodone Measured With 100 Millimeter Visual Analog Scale — -13.81; -9.67 units on a scale
N/A N=321 Subthreshold Opioid Use Disorder Prevention (STOP) Trial
Opioid-use Disorder
Primary: Days of Risky Opioid Use in Past 180 Days — 12.2; 15.5 days
N/A N=55 Clinical Decision Support for Opioid Use Disorders in Medical Settings: Usability Testing in an EMR
Opioid-use Disorder
Primary: Intervention PCP Confidence in Assessing and Treating OUD — 6; 11; 8; 1 Participants
N/A N=1,731 Opioid Use Disorder in the Emergency Department: CTN 0069
Opioid Use Disorder
Primary: Implementation (Considered the Primary Outcome) — 2; 53 Participants — p=<0.001
N/A N=16 Usability Testing for the Reward-based Technology to Improve OUD Treatment
Opioid-use Disorder · Contingency Management · Medication for Opioid-use Disorder
Primary: OARSCM Usability - Phase 1 Usability — 12 Participants
Phase 4 N=105 Bupropion for ADHD in Adolescents With Substance Use Disorder
Attention Deficit Hyperactivity Disorder · Nicotine Dependence · Cannabis Use Disorder
Primary: Change in ADHD Rating Scale (ADHD-RS) Total Score — -14.2; -13.8 units on a scale
Phase 2 N=91 Pharmacotherapy & CM for Opioid and Cocaine Dependence
Cocaine Dependence
Primary: Average Number of Positive Urine Tests — 32; 30.2; 28.1; 31.4 urine tests
N/A N=23 Adjunctive Transcranial Stimulation to Reduce Impulsivity in Opiate Use Disorder
Opioid-use Disorder · Tobacco Use Disorder
Primary: Attentional Bias for Smoking Stimuli — 501.53; 406.70 milliseconds
N/A N=18 Atomoxetine/Attention Deficit/ Hyperactive Disorder (ADHD)/Substance Use Disorder (SUD)in a Residential Treatment Facility
Attention Deficit Hyperactivity Disorder
Primary: Change in Adult ADHD Investigator Symptom Rating Scale Score — 17.3 units on a scale
Phase 2 N=15 Cannabidiol on Reward- and Stress-related Neurocognitive Processes in Individuals With Opioid Use Disorder
Opioid-use Disorder
Primary: Change in Cue-reactivity — 0.7; 1.1; 0.9; 2.4 score on a scale
Phase 2 N=63 Oxytocin Suppresses Substance Use Disorders Associated With Chronic Stress
Alcohol Use Disorder · Stress Disorders, Post-Traumatic · Anxiety Disorders
Primary: Change in Craving to Use Alcohol Rating (Visual Analog Scale) — 0.076; -0.928 score on a scale
Phase 3 N=20 Non-Invasive Vagal Nerve Stimulation in Opioid Use Disorders
Substance-Related Disorders · Substance Use Disorders · Substance Abuse, Intravenous
Primary: Opioid Craving Using Visual Analogue Scale — 3.909; 6; 4.556; 5.5 score on a scale
Phase 4 N=33 Brain Indices of Stimulant Treatment in Drug-Naive Youth at Risk for Substance Use Disorder
Attention Deficit Disorder With Hyperactivity · Conduct Disorder · Substance Abuse
Primary: Change in fMRI Measure — -0.957100; 0.572517; -0.139000; 1.876717 BOLD signal
N/A N=129 rTMS for Stimulant Use Disorders
Cocaine Use Disorder · Methamphetamine Abuse · Cocaine Dependence
Primary: Percentage of Participants Who Receive at Least 20 Sessions of rTMS/Sham Over the Treatment Period. — 29; 40; 37; 23 Participants
Phase 3 N=74 Smoking Cessation & Opioid Dependence Treatment Integration
Smoking Cessation · Opioid Related Disorders
Primary: Recruitment, Assignment to Treatment, and Retention Rates — 40; 33; 15; 32 Participants
Phase 1 N=8 Reinforcing Effects of Marijuana and Opioids
Marijuana Use · Opioid Use
Primary: Self-Administration of Drug Units Earned — 0.00; 3.83; 3.67; 0.00 Number of drug units
Phase 2 N=326 Low Nicotine Content Cigarettes in Vulnerable Populations: Opioid Use Disorder
Tobacco Use Disorder
Primary: Number of Cigarettes Smoked Per Day — 22.54; 14.32; 11.76; 7.63 cigarettes per day
N/A N=63 Digital Intervention to Treat Anxiety and Depression Among Persons Receiving Treatment for Opioid Use Disorder
Opioid-use Disorder · Anxiety Disorders · Depressive Disorder
Primary: Change in Anxiety Symptoms as Assessed by Generalized Anxiety Disorder- Q-IV Scale — -1.8; -1.04; -2.47; -1.53 units on a scale — p=.755
N/A N=52 Prolonged Exposure Therapy for PTSD and Opioid Use Disorder
Post Traumatic Stress Disorder · Opioid-use Disorder
Primary: Change in Posttraumatic Stress Disorder (PTSD) Symptom Severity — -11.4; -12.8; -18.3 Score on a scale